Safety and Efficacy Study of Betamarc to Treat Loss of Weight and Appetite in Non-Small Cell Lung Cancer
The purpose of this study is to determine whether Betamarc is effective in improving the appetite and reversing weight loss in patients with advanced Non-Small Cell Lung Cancer.
Anorexia|Cachexia|Weight Loss|Carcinoma, Non-Small-Cell Lung
DRUG: Betamarc
Functional capacity (strength and endurance), body composition by DXA, inflammation, patient reported outcomes, anti-tumor response rate, 25 weeks
Adverse events, ECG, vital signs, clinical laboratory parameters and physical examination, 25 weeks
The purpose of this study is to determine whether Betamarc is effective in improving the appetite and reversing weight loss in patients with advanced Non-Small Cell Lung Cancer.